Using technology to deliver therapy for children and young people is as effective as traditional face-to-face therapy, according to new research.
Latest news on BioNTech’s Friday buyout; Unpacking Sarepta’s Duchenne data; Pfizer’s post-Covid plans; Eli Lilly, AstraZeneca’s gene editing deals; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit